The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ikaros expression levels to predict response and survival following pomalidomide and dexamethasone in multiple myeloma (MM).
Yuan Xiao Zhu
No relevant relationships to disclose
Esteban Braggio
No relevant relationships to disclose
Chang-Xin Shi
No relevant relationships to disclose
K. Martin Kortüm
No relevant relationships to disclose
Laura A Bruins
No relevant relationships to disclose
Jessica E Schmidt
No relevant relationships to disclose
Xiu-bao Chang
No relevant relationships to disclose
Paul Langlais
No relevant relationships to disclose
Luo Moulun
No relevant relationships to disclose
Patrick Jedlowski
No relevant relationships to disclose
Betsy LaPlant
No relevant relationships to disclose
Kristina M Laumann
No relevant relationships to disclose
Rafael Fonseca
Consultant or Advisory Role - Amgen; Binding Site; Bristol-Myers Squibb; Celgene; Genzyme; Lilly; Medtronic; Millennium; Onyx; Otsuka
Research Funding - Celgene; Onyx
P. Leif Bergsagel
Consultant or Advisory Role - Onyx
Joseph Mikhael
Research Funding - Celgene; Onyx; Sanofi
Martha Lacy
Research Funding - Celgene
Mia D. Champion
No relevant relationships to disclose
A. Keith Stewart
No relevant relationships to disclose